Patterns and Predictors of Mortality After Waitlist Dropout of Patients With Hepatocellular Carcinoma Awaiting Liver Transplantation

被引:8
作者
Gorgen, Andre [1 ,2 ]
Rosales, Roizar [1 ]
Sadler, Erin [2 ]
Beecroft, Robert [3 ]
Knox, Jennifer [4 ]
Dawson, Laura A. [5 ]
Ghanekar, Anand [1 ,2 ]
Grant, David [1 ,2 ]
Greig, Paul D. [1 ,2 ]
Sapisochin, Gonzalo [1 ,2 ]
机构
[1] Univ Toronto, Univ Hlth Network, Multiorgan Transplant Program, Toronto, ON, Canada
[2] Univ Toronto, Dept Gen Surg, Toronto, ON, Canada
[3] Univ Toronto, Univ Hlth Network, Div Intervent Radiol, Joint Dept Imaging, Toronto, ON, Canada
[4] Univ Toronto, Princess Margaret Canc Ctr, Dept Med Oncol, Toronto, ON, Canada
[5] Univ Toronto, Princess Margaret Canc Ctr, Dept Radiat Oncol, Radiat Med Program, Toronto, ON, Canada
关键词
SURVIVAL; MODEL; RISK; CANDIDATES; DIAGNOSIS; RATES;
D O I
10.1097/TP.0000000000002616
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Background. There is a lack of information about survival after dropout from the liver transplant waiting list. Therefore, we aimed to assess the overall survival, and risk factors for death, after waiting list dropout due to hepatocellular carcinoma (HCC) progression. Methods. We assessed patients who dropped out of the liver transplant waiting list between 2000 and 2016 in a single, large academic North American center. Patients were divided into 3 groups according to the types of HCC progression: locally advanced disease (LAD), extrahepatic disease (EHD), and macrovascular invasion (MVI). The primary outcome was overall survival. Survival was assessed by the Kaplan-Meier method. Predictors of death after dropout were assessed by multivariable Cox regression. Results. During the study period, 172 patients dropped out due to HCC progression. Of those, 37 (21.5%), 74 (43%), and 61 (35.5%) dropped out due to LAD, EHD, and MVI, respectively. Median survival according to cause of dropout (LAD, EHD, or MVI) was 1.0, 4.4, or 3.3 months, respectively (P = 0.01). Model for End-stage Liver Disease (MELD) score (hazard ratio [HR], 1.04; 95% confidence interval [CI], 1.01-1.08), alcoholic liver disease (HR, 1.66; 95% CI, 1.02-2.71), and alpha-fetoprotein >1000 ng/mL (HR, 1.86; 95% CI, 1.22-2.84) were predictors of mortality after dropout. Dropout due to EHD (HR, 0.61; 95% CI, 0.38-0.98) and undergoing treatment after dropout were protective factors (HR, 0.32; 95% CI, 0.21-0.48) for death. Conclusions. Patient prognosis after dropout is dismal. However, a subgroup of patients may have longer survival. The present study identifies the patterns of waitlist dropout in patients with HCC and provides evidence for the effectiveness of treatment strategies offered to HCC patients after dropout.
引用
收藏
页码:2136 / 2143
页数:8
相关论文
共 32 条
[1]  
[Anonymous], E STAT ORG TRANSPL W
[2]   Evidence-Based Diagnosis, Staging, and Treatment of Patients With Hepatocellular Carcinoma [J].
Bruix, Jordi ;
Reig, Maria ;
Sherman, Morris .
GASTROENTEROLOGY, 2016, 150 (04) :835-853
[3]   Management of Hepatocellular Carcinoma: An Update [J].
Bruix, Jordi ;
Sherman, Morris .
HEPATOLOGY, 2011, 53 (03) :1020-1022
[4]   A Meta-Analysis of Survival Rates of Untreated Patients in Randomized Clinical Trials of Hepatocellular Carcinoma [J].
Cabibbo, Giuseppe ;
Enea, Marco ;
Attanasio, Massimo ;
Bruix, Jordi ;
Craxi, Antonio ;
Camma, Calogero .
HEPATOLOGY, 2010, 51 (04) :1274-1283
[5]   Alcohol recidivism impairs long-term patient survival after orthotopic liver transplantation for alcoholic liver disease [J].
Cuadrado, A ;
Fábrega, E ;
Casafont, F ;
Pons-Romero, F .
LIVER TRANSPLANTATION, 2005, 11 (04) :420-426
[6]   The added value of quality of life (QoL) for prognosis of overall survival in patients with palliative hepatocellular carcinoma [J].
Diouf, Momar ;
Filleron, Thomas ;
Barbare, Jean-Claude ;
Fin, Loic ;
Picard, Carl ;
Bouche, Olivier ;
Dahan, Laetitia ;
Paoletti, Xavier ;
Bonnetain, Franck .
JOURNAL OF HEPATOLOGY, 2013, 58 (03) :509-521
[7]   Liver Transplantation for Hepatocellular Carcinoma: A Model Including α-Fetoprotein Improves the Performance of Milan Criteria [J].
Duvoux, Christophe ;
Roudot-Thoraval, Francoise ;
Decaens, Thomas ;
Pessione, Fabienne ;
Badran, Hanaa ;
Piardi, Tullio ;
Francoz, Claire ;
Compagnon, Philippe ;
Vanlemmens, Claire ;
Dumortier, Jerome ;
Dharancy, Sebastien ;
Gugenheim, Jean ;
Bernard, Pierre-Henri ;
Adam, Rene ;
Radenne, Sylvie ;
Muscari, Fabrice ;
Conti, Filomena ;
Hardwigsen, Jean ;
Pageaux, Georges-Philippe ;
Chazouilleres, Olivier ;
Salame, Ephrem ;
Hilleret, Marie-Noelle ;
Lebray, Pascal ;
Abergel, Armand ;
Debette-Gratien, Marilyne ;
Kluger, Michael D. ;
Mallat, Ariane ;
Azoulay, Daniel ;
Cherqui, Daniel .
GASTROENTEROLOGY, 2012, 143 (04) :986-+
[8]   Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial [J].
El-Khoueiry, Anthony B. ;
Sangro, Bruno ;
Yau, Thomas ;
Crocenzi, Todd S. ;
Kudo, Masatoshi ;
Hsu, Chiun ;
Kim, Tae-You ;
Choo, Su-Pin ;
Trojan, Jorg ;
Welling, Theodore H., III ;
Meyer, Tim ;
Kang, Yoon-Koo ;
Yeo, Winnie ;
Chopra, Akhil ;
Anderson, Jeffrey ;
dela Cruz, Christine ;
Lang, Lixin ;
Neely, Jaclyn ;
Tang, Hao ;
Dastani, Homa B. ;
Melero, Ignacio .
LANCET, 2017, 389 (10088) :2492-2502
[9]  
European Assoc Study Liver, 2018, J HEPATOL, V69, P182, DOI 10.1016/j.jhep.2018.03.019
[10]   MELD Score Less Than 15 Predicts Prolonged Survival After Transjugular Intrahepatic Portosystemic Shunt for Refractory Ascites After Liver Transplantation [J].
Feyssa, Eyob ;
Ortiz, Jorge ;
Grewal, Kevin ;
Azhar, Ashaur ;
Parsikia, Afshin ;
Tufail, Kashif ;
Hashemi, Nikroo ;
Brady, Paul ;
Araya, Victor .
TRANSPLANTATION, 2011, 91 (07) :786-792